- Trials with a EudraCT protocol (184)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
184 result(s) found for: Lactate dehydrogenase.
Displaying page 1 of 10.
EudraCT Number: 2005-002274-30 | Sponsor Protocol Number: BRD/05/11 | Start Date*: 2005-12-14 |
Sponsor Name:University College London | ||
Full Title: A Study to assess the safety, efficacy and tolerability of Rituximab(Mabthera) in combination with Plasma Exchange in patients with Acute Thrombotic Thrombocytopenia Purpura. | ||
Medical condition: Thrombotic Thrombocytopenia Purpura | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001028-16 | Sponsor Protocol Number: EARLY-DEX | Start Date*: 2021-05-21 |
Sponsor Name:Fundación para la Investigación e Innovación Biomédica (FIIB) del Hospital Universitario Infanta Leonor y Hospital Unive | ||
Full Title: DEXamethasone EARLY administration in hospitalized patients with Covid-19 pneumonia and high risk of developing acute respiratory distress syndrome | ||
Medical condition: Hospitalized patients with Covid-19 pneumonia who do not require oxygen therapy on admission associated with at least two of the three following factors related with severe Covid-19: lactate dehydr... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003522-16 | Sponsor Protocol Number: RA101495-01.201 | Start Date*: 2017-06-20 | |||||||||||
Sponsor Name:Ra Pharmaceuticals, Inc. | |||||||||||||
Full Title: A PHASE 2 MULTICENTER,OPEN-LABEL, UNCONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RA101495 IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLO... | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) HU (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016966-97 | Sponsor Protocol Number: CAD01 | Start Date*: 2010-06-08 | |||||||||||
Sponsor Name:Universitätsklinikum Essen | |||||||||||||
Full Title: Therapy for Chronic Cold Agglutinin Disease: A Prospective, Non-Randomized, Multi-Center Study Demonstrating the Efficacy of Terminal Complement Inhibition in Patients with Cold Agglutinin Disease ... | |||||||||||||
Medical condition: Cold agglutinin disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001172-15 | Sponsor Protocol Number: APN01-01-COVID19 | Start Date*: 2020-04-08 |
Sponsor Name:APEIRON Biologics AG | ||
Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19 | ||
Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2020-005854-90 | Sponsor Protocol Number: ANX005-CAD-01 | Start Date*: 2021-02-11 |
Sponsor Name:Annexon, Inc. | ||
Full Title: A Phase 2, Single-Center, Open-Label, Repeat-Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of Intravenous ANX005 in Participants with Primary... | ||
Medical condition: Primary Cold Agglutinin Disease (CAD) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-002025-11 | Sponsor Protocol Number: ALXN1210-PNH-301 | Start Date*: 2016-12-02 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) BE (Completed) CZ (Completed) DK (Prematurely Ended) PT (Prematurely Ended) FI (Prematurely Ended) ES (Ongoing) NL (Completed) AT (Completed) EE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002026-36 | Sponsor Protocol Number: ALXN1210-PNH-302 | Start Date*: 2017-05-30 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001277-23 | Sponsor Protocol Number: ARGX-113-2007 | Start Date*: 2022-10-26 | |||||||||||
Sponsor Name:argenx BV | |||||||||||||
Full Title: A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Phar... | |||||||||||||
Medical condition: Active Idiopathic Inflammatory Myopathy (IIM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) BE (Trial now transitioned) LT (Trial now transitioned) SE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) ES (Trial now transitioned) PT (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) BG (Trial now transitioned) GR (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006686-32 | Sponsor Protocol Number: EC07/90573 | Start Date*: 2008-05-22 |
Sponsor Name:FUNDACIÓN INVESTIGACIÓN BIOMEDICA DEL HOSPITAL CLINICO SAN CARLOS | ||
Full Title: Identificación de biomarcadores proteicos asociados a resistencia a la aspirina y a tienopiridinas en pacientes con cardiopatía isquémica establecida. (ESTUDIO BIRAT). Identification of new protei... | ||
Medical condition: To determine proteins in plasma, leukocytes and platelets associated with aspirin resistance syndrome in stable coronary artery disease patients that may allow us to identify them.It is probably th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-009882-33 | Sponsor Protocol Number: TE-2009-01 | Start Date*: 2010-06-10 |
Sponsor Name:St Bartholomew's and The London NHS Trust | ||
Full Title: A multi-centre phase II study using Carboplatin AUC-10 for metastatic seminoma with IGCCCG good prognosis disease - therapy directed by initial metabolic response on PET-CT [CAR-PET] | ||
Medical condition: Metastatic seminoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001284-20 | Sponsor Protocol Number: BIOGIO | Start Date*: 2017-07-05 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: The effects of the proton pump inhibitor esomeprazole on the bioavailability of afatinib (Giotrif®) in patients with non-small cell lung cancer (NSCLC) 'the BIO-GIO study' | ||
Medical condition: Non small cell lung cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004008-71 | Sponsor Protocol Number: ELDORADO | Start Date*: 2017-01-19 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: The effect of curcumin and piperine on the pharmacokinetics of tamoxifen in patients with estrogen receptor positive breast cancer ‘the ELDORADO study’ | ||
Medical condition: Estrogen receptor positive breast cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-000823-38 | Sponsor Protocol Number: CABADARO | Start Date*: 2020-05-08 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: Study on the pharmacokinetic interaction between cabazitaxel and darolutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. | ||
Medical condition: metastatic castration-resistant prostate cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-003440-74 | Sponsor Protocol Number: ALXN1210-PNH-401 | Start Date*: 2020-05-14 | |||||||||||
Sponsor Name:Alexion Pharmaceuticals Inc. | |||||||||||||
Full Title: Phase 4, Single-Arm Study of Ravulizumab in Adult Participants with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with High-Dose Eculizumab | |||||||||||||
Medical condition: Paroxysmal nocturnal hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004995-17 | Sponsor Protocol Number: NL7507301820 | Start Date*: 2021-03-11 |
Sponsor Name:AMsterdam UMC-AMC | ||
Full Title: Low dose iron chelation as TReatment of Oxidative stress in Sickle cell disease; TROS study | ||
Medical condition: Sickle cell disease (an hereditary hemoglobinopathy) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-002795-42 | Sponsor Protocol Number: C04-002 | Start Date*: 2005-02-16 | |||||||||||
Sponsor Name:ALEXION PHARMACEUTICALS INCORPORATED | |||||||||||||
Full Title: Safety in Hemolytic PNH Patients Treated with Eculizumab: A Multi-center Open-label Research Design Study | |||||||||||||
Medical condition: paroxysmal nocturnal hemoglobinuria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IE (Completed) DE (Completed) GB (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001418-27 | Sponsor Protocol Number: 20150168 | Start Date*: 2019-01-29 | |||||||||||
Sponsor Name:Amgen Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY EVALUATING THE EFFICACY AND SAFETY OF ABP 959 COMPARED WITH ECULIZUMAB IN ADULT SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) NO (Completed) SI (Completed) IE (Completed) FI (Completed) SE (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003350-80 | Sponsor Protocol Number: APHP190843 | Start Date*: 2020-01-15 |
Sponsor Name:Université de Sherbrooke | ||
Full Title: Lessening Organ Dysfunction with VITamin C (LOVIT) | ||
Medical condition: Sepsis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000164-93 | Sponsor Protocol Number: 1000000 | Start Date*: 2006-05-10 |
Sponsor Name:Department of Anesthesiology University Hospital Center | ||
Full Title: Effect of Nutritional Support on Liver Integrity during General Anesthesia for Laparoscopic Cholecystectomy. A Pilot Study | ||
Medical condition: To the best of our knowledge, there is no clinical study on the protective effect of nutritional support on the liver in the perioperative setting using clinical and biological variables. Regarding... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
